Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short term Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Short term Debt for 12 consecutive years, with $41.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt changed N/A to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.2 million, a N/A change, with the full-year FY2025 number at $41.2 million, changed N/A from a year prior.
  • Short term Debt was $41.2 million for Q4 2025 at Cytokinetics, up from $17.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $41.2 million in Q4 2025 to a low of $958000.0 in Q4 2022.
  • A 4-year average of $14.4 million and a median of $11.7 million in 2025 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 52.78% in 2025; the steepest drop was 1.56% in 2025.
  • Cytokinetics' Short term Debt stood at $16.9 million in 2021, then plummeted by 94.32% to $958000.0 in 2022, then surged by 1204.8% to $12.5 million in 2024, then skyrocketed by 229.45% to $41.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Short term Debt are $41.2 million (Q4 2025), $17.3 million (Q3 2025), and $17.6 million (Q2 2025).